Journal article
Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non–Small Cell Lung Cancer
Abstract
BACKGROUND: The NCIC Clinical Trials Group conducted the BR.21 trial, a randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor) in patients with previously treated advanced non-small cell lung cancer. This trial accrued patients between August 14, 2001, and January 31, 2003, and found that overall survival and quality of life were improved in the erlotinib arm than in the placebo arm. …
Authors
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao M-S; Evans WK; Shepherd FA
Journal
Journal of the National Cancer Institute, Vol. 102, No. 5, pp. 298–306
Publisher
Oxford University Press (OUP)
Publication Date
March 3, 2010
DOI
10.1093/jnci/djp518
ISSN
0027-8874
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAgedAngiogenesis InhibitorsBiomarkers, TumorCanadaCarcinoma, Non-Small-Cell LungCost-Benefit AnalysisDrug CostsErbB ReceptorsErlotinib HydrochlorideFemaleHospitalizationHumansInternational CooperationLung NeoplasmsMaleMiddle AgedMulticenter Studies as TopicProtein Kinase InhibitorsProtein-Tyrosine KinasesQuinazolinesRandomized Controlled Trials as TopicRetrospective StudiesTreatment Outcome